| |
Report |
Presentation |
Webcast |
|
March 14, 2022
Oasmia Pharmaceutical – Aktiedagen Stockholm
|
|
|
|
|
January 19, 2022
Rights Issue Presentation at Erik Penser Bank
|
|
|
|
|
December 2, 2021
Oasmia - Presentation Erik Penser Bank
|
|
|
|
|
December 2, 2021
Presentation at Stora Aktiedagen Stockholm
|
|
|
|
|
October 21, 2021
Interview Erik Penser Bank
|
|
|
|
|
September 29, 2021
Naventus LifeScience Summit
|
|
|
|
|
September 7, 2021
Presentation at Aktiedagen Stockholm
|
|
|
|
|
June 11, 2021
Aktiespararna: Interview with Oasmia Pharmaceutical
|
|
|
|
|
April 12, 2021
Cantrixil abstract from Final Phase I Data at the 2021 AACR Annual Meeting
|
|
|
|
|
March 11, 2021
Sachs 14th Annual European Life Sciences CEO Forum, Virtual
|
|
|
|
|
March 1, 2021
Oasmia acquires global development and commercialization rights for Cantrixil
|
|
|
|
|
February 10, 2021
Swiss Nordic Bio
|
|
|
|
|
January 19, 2021
SEB Digital Healthcare Seminar Presentation
|
|
|
|
|
December 3, 2020
Oasmia’s Partner Elevar Provides an Update on Apealea Development Plans in Ovarian Cancer
|
|
|
|
|
November 11, 2020
Investival Showcase 11-16 November 2020, Virtual Conference
|
|
|
|
|
29 October, 2020
BIO-Europe®, Virtual Conference
|
|
|
|
|
October 7, 2020
Oasmia Erik Penser Cancer Day Presentation
|
|
|
|
|
September 24, 2020
Oasmia Erik Penser Investor Event Presentation
|
|
|
|
|
September 21, 2020
Presentation at Sachs Biotech in Europe Forum
|
|
|
|
|
September 15, 2020
Aktiedagen Digitalt
|
|
|
|
|
July 30, 2020
Analysguiden: Interview with Oasmia
|
|
|
|
|
June 10, 2020
Company Presentation Aktiespararna
|
|
|
|
|
June 3, 2020
Avanza Börsdag
|
|
|
|
|
May 13, 2020
Strategic Review Presentation
|
|
|
|
|
March 25, 2020
Elevar deal
|
|
|
|
|
February 14, 2020
Oasmia appoints new CEO
|
|
|
|
